BIOCON vs SHILPAMED: Stock Comparison

Biocon Limited vs Shilpa Medicare Limited

Live data: 22 July 2026, 3:01 PM IST • Source: NSE and company filings

Biocon Limited is the larger company by market capitalisation. Biocon Limited shows a higher dividend yield, while Shilpa Medicare Limited shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biocon Limited and Shilpa Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOCON is more favourable on 2 of 13 scored metrics and SHILPAMED on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BIOCON is the larger company
₹70,989 Cr vs ₹12,107 Cr
P/E Ratio
SHILPAMED has a lower P/E
51.29x vs 185.25x
P/B Ratio
BIOCON has a lower P/B
2.1x vs 4.82x
EPS
SHILPAMED has higher earnings per share
₹12.44 vs ₹2.86
Dividend Yield
BIOCON has a higher dividend yield
0.11% vs 0.08%
Revenue Growth (TTM YoY)
SHILPAMED has faster revenue growth
31.5% vs 2.3%
EPS Growth (TTM YoY)
SHILPAMED has faster EPS growth
644.6% vs -72.5%
Qtr Sales Growth
SHILPAMED has stronger quarterly sales growth
32.1% vs 2.25%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOCONSHILPAMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOCONSHILPAMED
Live Price₹437.75₹614.55
Day Change-0.58%-3.98%
Volume51.58 L4.81 L
52-Week High₹447.15₹860
52-Week Low₹331₹259.5
Distance from 52W High-2.1%-28.54%

Valuation

MetricBIOCONSHILPAMED
Market Cap₹70,989 Cr₹12,107 Cr
P/E Ratio185.25x51.29x
P/B Ratio2.1x4.82x
EPS₹2.86₹12.44
Book Value₹210.14₹132.46
Dividend Yield0.11%0.08%

Growth

MetricBIOCONSHILPAMED
Revenue Growth (TTM YoY)2.3%31.5%
EPS Growth (TTM YoY)-72.5%644.6%
Qtr Sales Growth2.25%32.1%
Qtr Profit Growth-62%148%

Profitability & Leverage

MetricBIOCONSHILPAMED
ROE1.4%9.4%
ROCE3.75%11%
Net Margin2.29%15.82%
Operating Margin20.4%28.2%
Debt to Equity0.45x0.25x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOCONSHILPAMED
Promoter Holding29.73% 0.17 pp40.13%
FII Holding8.16% 0.64 pp11.38% 0.3 pp
DII Holding23.37% 0.7 pp8.05% 0.53 pp
Public Holding23.74% 0.33 pp40.43% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biocon Limited and Shilpa Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.